A Randomized, Double-Blind, Active Control, Multicenter, Dose-Finding Study of Lipegfilgrastim (XM22) in Breast Cancer Patients Receiving Myelosuppressive Therapy
Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-014-3120-6
Full Text
Open PDFAbstract
Available in full text
Date
September 27, 2014
Authors
Publisher
Springer Science and Business Media LLC